Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

John F de Groot, MD
Published: Monday, Nov 17, 2014

John F de Groot, MD, neuro-oncologist, The University of Texas MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

In a trial, mice were treated with altiratinib alone, bevacizumab alone, or a combination of the two agents. De Groot says the combination dramatically reduced tumor volume and tumor invasion.

De Groot speculates that the combination worked so well because it was able to block myeloid cell infiltration and reduce angiogenesis in order to decrease tumor cell invasion.

​

<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting

John F de Groot, MD, neuro-oncologist, The University of Texas MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

In a trial, mice were treated with altiratinib alone, bevacizumab alone, or a combination of the two agents. De Groot says the combination dramatically reduced tumor volume and tumor invasion.

De Groot speculates that the combination worked so well because it was able to block myeloid cell infiltration and reduce angiogenesis in order to decrease tumor cell invasion.

​

<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x